AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Portfolio Pulse from
AIM ImmunoTech has announced Dr. Paul Goepfert as the principal investigator for a clinical study involving Ampligen and FluMist as a vaccine for avian influenza. The study aims to use Ampligen as a vaccine adjuvant to enhance cross-reactivity to various influenza strains.
February 28, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech is initiating a clinical study with Ampligen and FluMist to develop a vaccine for avian influenza, potentially enhancing its product portfolio and market position.
The announcement of a new clinical study involving Ampligen as a vaccine adjuvant could lead to positive investor sentiment, as it represents a potential expansion of AIM's product offerings and market reach. The involvement of a principal investigator like Dr. Paul Goepfert adds credibility to the study.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100